Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 8, Number 8—August 2002

Research

Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan

Po-Ren Hsueh*, Lee-Jene Teng*, Cheng-Yi Chen*, Wen-Hwei Chen*, Shen-Wu Ho*Comments to Author , and Kwen-Tay Luh*
Author affiliations: *National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;

Main Article

Figure 1

Annual consumption (gram/patient-day x 1,000) of carbapenems (imipenem and meropenem), extended-spectrum cephalosporins (cefotaxime, ceftroaxone, ceftazidime, and cefepime), ciprofloxacin, aminoglycosides (gentamicin, tobramycin, netilmicin, and amikacin) and percent of isolates of imipenem-resistant and pandrug-resistant Acinetobacter baumannii (PDRAB) at the National Taiwan University Hospital, 1993–2000.

Figure 1. Annual consumption (gram/patient-day x 1,000) of carbapenems (imipenem and meropenem), extended-spectrum cephalosporins (cefotaxime, ceftroaxone, ceftazidime, and cefepime), ciprofloxacin, aminoglycosides (gentamicin, tobramycin, netilmicin, and amikacin) and percent of isolates of imipenem-resistant and pandrug-resistant Acinetobacter baumannii (PDRAB) at the National Taiwan University Hospital, 1993–2000.

Main Article

TOP